DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission

Science

Volumn 281, Issue 5378, 1998, Pages 838-842

  Fienberg, A A ^a   Hiroi, N ^a   Mermelstein, P G ^a   Song, W J ^a   Snyder, G L ^a   Nishi, A ^a   Cheramy, A ^a   O'Callaghan, J P ^a   Miller, D B ^a   Cole, D G ^a   Corbett, R ^a   Haile, C N ^a   Cooper, D C ^a   Onn, S P ^a   Grace, A A ^a   Ouimet, C C ^a   White, F J ^a   Hyman, S E ^a   Surmeier, D J ^a   Girault, J A ^a   Nestler, E J ^a   Greengard, P ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; PHOSPHOPROTEIN DARPP 32; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; FOREBRAIN; GENE DISRUPTION; GENE EXPRESSION REGULATION; MOUSE; NERVE CELL MEMBRANE POTENTIAL; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMPHETAMINES; ANIMALS; BEHAVIOR, ANIMAL; CALCIUM; COCAINE; CORPUS STRIATUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION REGULATION; GENE TARGETING; GENES, FOS; GLUTAMIC ACID; MALE; MICE; MICE, INBRED C57BL; NA(+)-K(+)-EXCHANGING ATPASE; NERVE TISSUE PROTEINS; NEURONS; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEINS; PHOSPHORYLATION; RACLOPRIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; SALICYLAMIDES; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0032493904     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.281.5378.838     Document Type: Article

References (53)

1. P. W. Kalivas and J. Stewart, Brain Res. Rev. 16, 223 (1991).
2. C. F. Koob, Trends Pharmacol. Sci. 13, 177 (1992); E. J. Nestler and G. K. Aghajanian, Science 278, 58 (1997).
3. C. F. Koob, Trends Pharmacol. Sci. 13, 177 (1992); E. J. Nestler and G. K. Aghajanian, Science 278, 58 (1997).
4. G. V. Williams and P. S. Goldman-Rakic, Nature 376, 572 (1995).
5. R. L. Albin, A. Young, J. B. Penney, Trends Neurosci. 12, 366 (1989); M. B. Knable and D. R. Weinberger, J. Psychopharmacol. 11, 123 (1997); G. F. Koob and M. Le Moal, Science 278, 52 (1997).
6. R. L. Albin, A. Young, J. B. Penney, Trends Neurosci. 12, 366 (1989); M. B. Knable and D. R. Weinberger, J. Psychopharmacol. 11, 123 (1997); G. F. Koob and M. Le Moal, Science 278, 52 (1997).
7. R. L. Albin, A. Young, J. B. Penney, Trends Neurosci. 12, 366 (1989); M. B. Knable and D. R. Weinberger, J. Psychopharmacol. 11, 123 (1997); G. F. Koob and M. Le Moal, Science 278, 52 (1997).
8. S. I. Walaas, D. W. Aswad, P. Greengard, Nature 301, 69 (1983); S. I. Walaas, A. C. Nairn, P. Greengard, J. Neurosci. 3, 302 (1983).
9. S. I. Walaas, D. W. Aswad, P. Greengard, Nature 301, 69 (1983); S. I. Walaas, A. C. Nairn, P. Greengard, J. Neurosci. 3, 302 (1983).
10. C. C. Ouimet, P. E. Miller, H. C. Hemmings Jr., S. I. Walaas, P. Greengard, J. Neurosci. 4, 114 (1984); C. C. Ouimet and P. Greengard, J. Neurocytol. 19, 39 (1990); K. C. Langley, C. Bergson, P. Greengard, C. C. Ouimet, Neuroscience 78, 977 (1997).
11. C. C. Ouimet, P. E. Miller, H. C. Hemmings Jr., S. I. Walaas, P. Greengard, J. Neurosci. 4, 114 (1984); C. C. Ouimet and P. Greengard, J. Neurocytol. 19, 39 (1990); K. C. Langley, C. Bergson, P. Greengard, C. C. Ouimet, Neuroscience 78, 977 (1997).
12. C. C. Ouimet, P. E. Miller, H. C. Hemmings Jr., S. I. Walaas, P. Greengard, J. Neurosci. 4, 114 (1984); C. C. Ouimet and P. Greengard, J. Neurocytol. 19, 39 (1990); K. C. Langley, C. Bergson, P. Greengard, C. C. Ouimet, Neuroscience 78, 977 (1997).
13. H. C. Hemmings Jr., K. R. Williams, W. H. Konigsberg, P. Greengard, J. Biol. Chem. 259, 14486 (1984).
14. A. Nishi et al., J. Neurosci. 17, 8147 (1997).
15. P. Greengard et al., Brain Res. Rev. 26, 274 (1998).
16. H. C. Hemmings Jr., P. Greengard, H. Y. Tung, P. Cohen, Nature 310, 503 (1984).
17. S. Shenolikar and A. C. Nairn, Adv. Sec. Messenger Phosphoprotein Res. 23, 1 (1991).
18. 6 levels of backcrossing. Backcrossing was carried out into the C57BL/6 inbred mouse strain (from The Jackson Laboratory). None of the phenotypes presented appeared to be influenced by the level of backcrossing. All the mice used were males, except for the methamphetamine toxicity experiments, in which females were used. All mice were 3 to 6 months of age, except when we examined the electrophysiology of calcium channels in ∼3-to 5-week-old mice. DARPP-32 mutant mice showed no obvious differences from wild-type mice in measures of over-all health such as weight and food intake. Matings of heterozygotes yielded wild-type, heterozygote, and mutant genotypes in Mendelian proportions and with equal percentages of males and females.
19. C. C. Ouimet, unpublished observations.
20. The size and gross morphological appearance of the brains of the mutant mice were normal. In addition, the densities of neurons, nerve terminals, and dendritic spines in the striatum were indistinguishable from those of wild-type controls (13). We used immunocytochemistry to examine major subsets of striatal neurons in these mice. Calbindin, a marker for the striatal matrix compartment [C. R. Gerfen, Trends Neurosci. 15, 133 (1992); A. M. Graybiel, ibid. 13, 244 (1990)], showed a normal pattern of distribution. Met-enkephalin, a marker for the striatal indirect pathway, also showed apparently normal immunoreactivity in the striatum and in its projection areas, the globus pallidus-ventral pallidum, in mutant mice. Dynorphin, a marker for the striatonigral direct pathway showed no apparent abnormality in the striatum or in the terminals of these neurons in ventral midbrain (substantia nigra and ventral tegmental area). Taken together, our findings indicate that if any defects occur during the development of the striatum they are subtle and unlikely to be responsible for the distinct phenotype in adult mutant mice reported here.
21. The size and gross morphological appearance of the brains of the mutant mice were normal. In addition, the densities of neurons, nerve terminals, and dendritic spines in the striatum were indistinguishable from those of wild-type controls (13). We used immunocytochemistry to examine major subsets of striatal neurons in these mice. Calbindin, a marker for the striatal matrix compartment [C. R. Gerfen, Trends Neurosci. 15, 133 (1992); A. M. Graybiel, ibid. 13, 244 (1990)], showed a normal pattern of distribution. Met-enkephalin, a marker for the striatal indirect pathway, also showed apparently normal immunoreactivity in the striatum and in its projection areas, the globus pallidus-ventral pallidum, in mutant mice. Dynorphin, a marker for the striatonigral direct pathway showed no apparent abnormality in the striatum or in the terminals of these neurons in ventral midbrain (substantia nigra and ventral tegmental area). Taken together, our findings indicate that if any defects occur during the development of the striatum they are subtle and unlikely to be responsible for the distinct phenotype in adult mutant mice reported here.
22. Striatal levels of D1-like and D2-like receptor binding as well as D1-like stimulated adenylyl cyclase were equivalent in wild-type and mutant mice (P. Svenningsson, B. Fredholm, J.-A. Girault, unpublished observations).
23. G. Snyder, A. Fienberg, I. Dulubova, A. C. Nairn, P. Greengard, Soc. Neurosci. Abstr. 22, 380 (1996).
24. 32P incorporation was quantitated by Phosphorlmager analysis (Molecular Dynamics).
25. C. Cepeda, N. A. Buchwald, M. S. Levine, Proc. Natl. Acad. Sci. U.S.A. 90, 9576 (1993).
26. C. S. Colwell and M. S. Levine, J. Neurosci. 15, 1704 (1995); M. S. Levine et al., ibid. 16, 5870 (1996).
27. C. S. Colwell and M. S. Levine, J. Neurosci. 15, 1704 (1995); M. S. Levine et al., ibid. 16, 5870 (1996).
28. T. Blank et al., Proc. Natl. Acad. Sci. U.S.A. 94, 14859 (1997).
29. A. M. Bertorello, J. F. Hopfield, A. Aperia, P. Greengard, Nature 347, 386 (1990).
30. A. Nishi, unpublished observations.
31. N. Uchimura, H. Higashi, S. Nishi, Brain Res. 375, 368 (1986); A. Akaike, Y. Ohno, M. Sasa, S. Takaori, ibid. 418, 262 (1987).
32. N. Uchimura, H. Higashi, S. Nishi, Brain Res. 375, 368 (1986); A. Akaike, Y. Ohno, M. Sasa, S. Takaori, ibid. 418, 262 (1987).
33. P. Calabresi, N. Mercuri, P. Stanzione, A. Stefani, G. Bernardi, Neuroscience 20, 757 (1987).
34. D. J. Surmeier, J. Eberwine, C. J. Wilson, A. Stefani, S. T. Kitai, Proc. Natl. Acad. Sci. U.S.A. 89, 10178 (1992); S. N. Schiffman, P.-M. Lledo, J.-D. Vincent, J. Physiol. (London) 483, 95 (1994).
35. D. J. Surmeier, J. Eberwine, C. J. Wilson, A. Stefani, S. T. Kitai, Proc. Natl. Acad. Sci. U.S.A. 89, 10178 (1992); S. N. Schiffman, P.-M. Lledo, J.-D. Vincent, J. Physiol. (London) 483, 95 (1994).
36. D. J. Surmeier, J. Bargas, H. C. Hemmings Jr., A. C. Nairn, P. Greengard, Neuron 14, 385 (1995).
37. S.-P. Onn and A. A. Grace, unpublished observations.
38. S. R. White, G. C. Harris, K. M. Imel, M. J. Wheaton, Brain Res. 681, 167 (1995).
39. J.-A. Girault, U. Spampinato, J. Glowinski, M. Besson, Neuroscience 19, 1109 (1986); B. Floran, J. Aceves, A. Sierra, D. Martinez-Fong, Neurosci. Lett. 116, 136 (1990).
40. J.-A. Girault, U. Spampinato, J. Glowinski, M. Besson, Neuroscience 19, 1109 (1986); B. Floran, J. Aceves, A. Sierra, D. Martinez-Fong, Neurosci. Lett. 116, 136 (1990).
41. J. P. O'Callaghan and D. B. Miller, J. Phamacol. Exp. Ther. 270, 741 (1994).
42. A. M. Graybiel, R. Mortalla, H. A. Robertson, Proc. Natl. Acad. Sci. U.S.A. 87, 6912 (1990); S. T. Young, L. J. Porrino, M. J. Iadarola, ibid. 88, 1291 (1991).
43. A. M. Graybiel, R. Mortalla, H. A. Robertson, Proc. Natl. Acad. Sci. U.S.A. 87, 6912 (1990); S. T. Young, L. J. Porrino, M. J. Iadarola, ibid. 88, 1291 (1991).
44. D. G. Cole, unpublished observations.
45. N. Hiroi et al., Proc. Natl. Acad. Sci. U.S.A. 94, 10397 (1997).
46. B. T. Hope et al., Neuron 13, 1235 (1994); H. E. Nye, B. T. Hope, M. B. Kelz, M. J. Iadarola, E. J. Nestler, J. Pharmacol. Exp. Ther. 275, 1671 (1995).
47. B. T. Hope et al., Neuron 13, 1235 (1994); H. E. Nye, B. T. Hope, M. B. Kelz, M. J. Iadarola, E. J. Nestler, J. Pharmacol. Exp. Ther. 275, 1671 (1995).
48. M. Xu et al., Cell 79, 945 (1994).
49. R. Corbett, unpublished observations.
50. Neurotransmitter outflow from striatal microdiscs and synaptosomes was measured as described [T. Galli et al., Neuroscience 50, 769 (1992)].
51. C. Konradi, R. L. Cole, K. Heckers, S. E., Hyman, J. Neurosci. 14, 5623 (1994).
52. R. G. Pertwee, Br. J. Pharmacol. 46, 753 (1972).
53. Supported by the A.P.D.A. (A.A.F.), U.S. Public Health Service grants MH40899 and DA10044 (P.G.), DA 08227 and DA 07359 (E.J.N.), and a grant from Ministère de l'Education Nationale, de l'Enseignement Superieur et de la Recherche (97H0003; J.-A.G.). We thank E. J. Robertson, A. Furley, A. Plump, and S. Tonegawa for valuable help in the initial phases of this work. We thank P. Ingrassia, E. Griggs, F. Artaud, and M. Lhirondel for excellent assistance.